These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 9830635

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
    Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Grillo-López AJ.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
    [Abstract] [Full Text] [Related]

  • 3. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA.
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [Abstract] [Full Text] [Related]

  • 4. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
    Bhat SA, Czuczman MS.
    Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
    [Abstract] [Full Text] [Related]

  • 5. Rituximab: an insider's historical perspective.
    Grillo-López AJ.
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):9-16. PubMed ID: 11226006
    [Abstract] [Full Text] [Related]

  • 6. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S, Pennel N, Reis M, Pinkerton P, Dubé I, Hewitt K, Berinstein NL.
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [Abstract] [Full Text] [Related]

  • 7. Monoclonal antibody treatment of solid tumors: a coming of age.
    Murray JL.
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):64-70; discussion 92-100. PubMed ID: 11236030
    [Abstract] [Full Text] [Related]

  • 8. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK.
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [Abstract] [Full Text] [Related]

  • 9. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Dillman RO.
    Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152
    [Abstract] [Full Text] [Related]

  • 10. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM, Younes A.
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [Abstract] [Full Text] [Related]

  • 11. Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma.
    Motta G, Cea M, Carbone F, Augusti V, Moran E, Patrone F, Nencioni A.
    J BUON; 2011 Aug; 16(1):9-15. PubMed ID: 21674844
    [Abstract] [Full Text] [Related]

  • 12. Rituximab: ongoing and future clinical development.
    Grillo-López AJ, Hedrick E, Rashford M, Benyunes M.
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):105-12. PubMed ID: 11842397
    [Abstract] [Full Text] [Related]

  • 13. Antibody therapy for non-Hodgkin's lymphoma.
    Ansell SM.
    Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
    [Abstract] [Full Text] [Related]

  • 14. Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma.
    Smith S, Sweetenham JW.
    Future Oncol; 2007 Jun; 3(3):255-62. PubMed ID: 17547519
    [Abstract] [Full Text] [Related]

  • 15. Clinical status and optimal use of rituximab for B-cell lymphomas.
    McLaughlin P, White CA, Grillo-López AJ, Maloney DG.
    Oncology (Williston Park); 1998 Dec; 12(12):1763-9; discussion 1769-70, 1775-7,. PubMed ID: 9874849
    [Abstract] [Full Text] [Related]

  • 16. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
    Paul F, Rossi JF, Cartron G.
    Rev Prat; 2010 Jan 20; 60(1):59-63. PubMed ID: 20222313
    [Abstract] [Full Text] [Related]

  • 17. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
    Molina A.
    Annu Rev Med; 2008 Jan 20; 59():237-50. PubMed ID: 18186705
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan 20; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 20. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma.
    Traullé C, Coiffier BB.
    Future Oncol; 2005 Jun 20; 1(3):297-306. PubMed ID: 16556002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.